2023 was a troublesome calendar year for your biopharma field, with a number of firms downsizing and restructuring their workforces to remain afloat. You will find signs of recovery, as mergers and acquisitions picked up throughout the pharmaceutical and daily life sciences marketplace during the latter part of 2023 and https://sites.google.com/view/bio-sites/blog